Contingencies - Narrative (Details) - USD ($) |
12 Months Ended | |||
|---|---|---|---|---|
Aug. 02, 2023 |
Jan. 18, 2023 |
Dec. 31, 2024 |
Sep. 30, 2025 |
|
| Loss Contingencies [Line Items] | ||||
| Gain (loss) from litigation settlement | $ 4,234,717 | |||
| Estimated loss contingency | $ 2,054,357 | |||
| Wendy Cunning Vs Skye Bioscience, Inc | ||||
| Loss Contingencies [Line Items] | ||||
| Total compensatory damages | $ 1,200,008 | |||
| Loss contingency, appeal bond | $ 9,080,202 | |||
| Wendy Cunning Vs Skye Bioscience, Inc | Economic Damages | ||||
| Loss Contingencies [Line Items] | ||||
| Total compensatory damages | $ 512,500 | |||
| Wendy Cunning Vs Skye Bioscience, Inc | Non-Economic Damages | ||||
| Loss Contingencies [Line Items] | ||||
| Total compensatory damages | 840,960 | |||
| Wendy Cunning Vs Skye Bioscience, Inc | Punitive Damages | ||||
| Loss Contingencies [Line Items] | ||||
| Total compensatory damages | $ 3,500,000 | |||
| Change in estimate for legal contingency | $ 151,842 |
| X | ||||||||||
- Definition Loss Contingency, Appeal Bond No definition available.
|
| X | ||||||||||
- Definition Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in loss contingency liability. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of damages awarded to the plaintiff in the legal matter. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Reflects the estimated amount of loss from the specified contingency as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|